लातविया - लातवियाई - Pārtikas un veterinārais dienests, Zemkopības ministrija

ražots es pēc sia "litada" pasūtījuma - kapsula

लातविया - लातवियाई - Zāļu valsts aģentūra

egis pharmaceuticals plc, hungary - sorafenibs - apvalkotā tablete - 200 mg

यूरोपीय संघ - लातवियाई - EMA (European Medicines Agency)

esteve pharmaceuticals gmbh - thiotepa - hematopoietic stem cell transplantation; neoplasms - antineoplastiski līdzekļi - thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients. thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients.

यूरोपीय संघ - लातवियाई - EMA (European Medicines Agency)

regeneron ireland designated activity company (dac) - cemiplimab - karcinoma, švamšā šūna - antineoplastiski līdzekļi - cutaneous squamous cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mcscc or lacscc) who are not candidates for curative surgery or curative radiation. basal cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (labcc or mbcc) who have progressed on or are intolerant to a hedgehog pathway inhibitor (hhi). non-small cell lung cancerlibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (nsclc) expressing pd-l1 (in ≥ 50% tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with nsclc expressing pd-l1 (in ≥ 1% of tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. cervical cancerlibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.

लातविया - लातवियाई - Pārtikas un veterinārais dienests, Zemkopības ministrija

sia ″oriola rĪga″ - kekss

लातविया - लातवियाई - Zāļu valsts aģentūra

viatris limited, ireland - pazopanibs - apvalkotā tablete - 200 mg

लातविया - लातवियाई - Zāļu valsts aģentūra

viatris limited, ireland - pazopanibs - apvalkotā tablete - 400 mg

लातविया - लातवियाई - Zāļu valsts aģentūra

stada arzneimittel ag, germany - posakonazols - zarnās šķīstošā tablete - 100 mg

लातविया - लातवियाई - Zāļu valsts aģentūra

sandoz d.d., slovenia - sorafenibs - apvalkotā tablete - 200 mg

लातविया - लातवियाई - Zāļu valsts aģentūra

sandoz d.d., slovenia - sorafenibs - apvalkotā tablete - 400 mg